In the last trading session, the stock price of PharmaCyte Biotech Inc (OTCQB:PMCB) declined more than 5% to close the day at $0.06. The decline came at a share volume of 2.83 million compared to average share volume of 2.38 million. PMCB has declined more than 59% so far in this year.
More recently, PharmaCyte reported that it recently saw its Oncology Advisory Board. This team was formed to help in finalizing and optimizing the clinical protocol and other trial related matters for company’s clinical study in subjects with LAPC. Representatives from the PharmaCyte and Advisory Board participated in an extensive teleconference and conversed on a number of clinical trial related matters, a big part which were intended to enhance the trial protocol and advance strategies to ensure that subject enrollment in the clinical study can be maximized.
Oncologists from numerous key institutions across the United States are participants on the Advisory Board. Some of these organizations are the Mayo Clinic, Duke University, the University of California, and others.
Kenneth L. Waggoner, the CEO of PharmaCyte, reported that they are extremely grateful to those leading oncologists who have accepted to join their Oncology Advisory Board to help them in finalizing their clinical study protocol and in sharing their views on the way to achieve their objective of making their therapy available to those people who desperately require an effective therapy for LAPC. They obtained invaluable input from these professionals in pancreatic cancer that should enable company to enter the clinic with the maximum possibility for success.
PharmaCyte is a renowned clinical stage biotechnology entity developing cellular therapies targeting cancer and diabetes depending upon a cellulose-linked live cell encapsulation know-how, which is termed as “Cell-in-a-Box®.” This unique technology will be applied as a platform upon which treatments for different forms of diabetes and cancer are being advanced.